Eli Lilly and Company said supply issues for its GLP-1/GIP dual agonist tirzepatide – the active ingredient in type 2 diabetes drug Mounjaro and obesity treatment Zepbound – largely have been resolved. The company increased its full-year overall sales guidance for 2024 by $3bn when it reported second quarter earnings on 8 August, largely on the strength of those two products, but with some contribution from its breast cancer drug Verzenio (abemaciclib).
Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn
Obesity, Diabetes Blockbusters Lead 36% Revenue Growth
Lilly now expects to bring in between $45.4bn and $46.6bn in total revenue this year, thanks mainly to continued growth for Mounjaro and Zepbound.
More from Earnings
More from Business
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.